Data
NOTE: A total of 278 participants included in analysis after removing exclusion criteria.
Descriptives
Patient demographics
|
Characteristic
|
Conventional (n=141)
|
Non-conventional (n=137)
|
Total (n=278)
|
P-value
|
|
Age (y)at the time of result: Mean (SD)
|
65.40 (15.10)
|
68.81 (14.64)
|
67.08 (14.95)
|
0.06
|
|
Age (y)at the time of result: N(%)
|
|
|
|
0.36
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
<65 years
|
60 (42.6)
|
50 (36.5)
|
110 (39.57)
|
|
|
≥65 years
|
81 (57.4)
|
87 (63.5)
|
168 (60.43)
|
|
|
Gender: N(%)
|
|
|
|
0.58
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Male
|
90 (63.8)
|
82 (59.9)
|
172 (61.87)
|
|
|
Female
|
51 (36.2)
|
55 (40.1)
|
106 (38.13)
|
|
|
Inpatient length of stay: Median (IQ range)
|
12.00 (6.00-24.00)
|
14.00 (8.00-25.00)
|
13.00 (7.00-24.75)
|
0.18
|
|
Height (cm): Mean (SD)
|
171.19 (10.34)
|
170.45 (10.39)
|
170.83 (10.35)
|
0.55
|
|
Weight (kg)within the week prior to dose: Mean (SD)
|
88.02 (26.93)
|
98.32 (41.03)
|
93.10 (34.92)
|
0.01
|
|
BMI: Median (IQ range)
|
28.93 (24.23-33.71)
|
29.45 (24.97-39.68)
|
29.10 (24.43-35.06)
|
0.13
|
|
BMI: N(%)
|
|
|
|
0.92
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
<30 kg/m2
|
77 (54.6)
|
73 (53.3)
|
150 (53.96)
|
|
|
≥30 kg/m2
|
64 (45.4)
|
64 (46.7)
|
128 (46.04)
|
|
|
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: Mean (SD)
|
50.35 (27.86)
|
48.33 (23.15)
|
49.25 (25.36)
|
0.60
|
|
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: N(%)
|
|
|
|
0.002
|
|
Missing
|
58 (41.1)
|
39 (28.5)
|
97 (34.89)
|
|
|
Stage 1: >=90 ml/min
|
0 (0.0)
|
2 (1.5)
|
2 (0.72)
|
|
|
Stage 2: 60-89 ml/min
|
37 (26.2)
|
26 (19.0)
|
63 (22.66)
|
|
|
Stage 3: 30-59 ml/min
|
21 (14.9)
|
49 (35.8)
|
70 (25.18)
|
|
|
Stag3 4/5: <30 ml/min
|
25 (17.7)
|
21 (15.3)
|
46 (16.55)
|
|
|
modified CG (mL/min): Mean (SD)
|
65.27 (36.25)
|
55.33 (33.27)
|
60.37 (35.11)
|
0.02
|
|
CrCl (mL/min): N(%)
|
|
|
|
0.003
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
<50 ml/min
|
52 (36.9)
|
76 (55.5)
|
128 (46.04)
|
|
|
≥50 ml/min
|
89 (63.1)
|
61 (44.5)
|
150 (53.96)
|
|
|
LMWH level: Mean (SD)
|
0.88 (0.35)
|
0.79 (0.32)
|
0.84 (0.34)
|
0.02
|
|
LMWH >1.0: N(%)
|
|
|
|
0.02
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
≤1.0
|
96 (68.1)
|
111 (81.0)
|
207 (74.46)
|
|
|
>1.0
|
45 (31.9)
|
26 (19.0)
|
71 (25.54)
|
|
|
LMWH
|
|
|
|
0.09
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
<0.5
|
13 (9.2)
|
23 (16.8)
|
36 (12.95)
|
|
|
≥0.5
|
128 (90.8)
|
114 (83.2)
|
242 (87.05)
|
|
|
Enoxaparin dose used (mg): Mean (SD)
|
88.19 (25.46)
|
77.55 (32.75)
|
82.95 (29.71)
|
0.003
|
|
Enoxaparin dose (mg/kg): Mean (SD)
|
1.01 (0.12)
|
0.83 (0.30)
|
0.92 (0.24)
|
<0.0001
|
|
Concurrent antiplatelet or anticoagulation treatment: N(%)
|
|
|
|
1.00
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
No
|
140 (99.3)
|
136 (99.3)
|
276 (99.28)
|
|
|
Yes
|
1 (0.7)
|
1 (0.7)
|
2 (0.72)
|
|
|
Clinical events after anticoagulation (choice=Death): N(%)
|
|
|
|
0.88
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Unchecked
|
129 (91.5)
|
127 (92.7)
|
256 (92.09)
|
|
|
Checked
|
12 (8.5)
|
10 (7.3)
|
22 (7.91)
|
|
|
Clinical events after anticoagulation (choice=ACS): N(%)
|
|
|
|
0.49
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Unchecked
|
141 (100.0)
|
136 (99.3)
|
277 (99.64)
|
|
|
Checked
|
0 (0.0)
|
1 (0.7)
|
1 (0.36)
|
|
|
Clinical events after anticoagulation (choice=VTE): N(%)
|
|
|
|
1.00
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Unchecked
|
139 (98.6)
|
135 (98.5)
|
274 (98.56)
|
|
|
Checked
|
2 (1.4)
|
2 (1.5)
|
4 (1.44)
|
|
|
Clinical events after anticoagulation (choice=Ischaemic stroke in hospital): N(%)
|
|
|
|
0.24
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Unchecked
|
141 (100.0)
|
135 (98.5)
|
276 (99.28)
|
|
|
Checked
|
0 (0.0)
|
2 (1.5)
|
2 (0.72)
|
|
|
Major bleeding in hospital: N(%)
|
|
|
|
0.53
|
|
Missing
|
1 (0.7)
|
1 (0.7)
|
2 (0.72)
|
|
|
Yes
|
5 (3.5)
|
8 (5.8)
|
13 (4.68)
|
|
|
No
|
135 (95.7)
|
128 (93.4)
|
263 (94.60)
|
|
|
Indication for enoxaparin(choose as many as apply) (choice=Pulmonary embolism): N(%)
|
|
|
|
0.24
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Unchecked
|
56 (39.7)
|
65 (47.4)
|
121 (43.53)
|
|
|
Checked
|
85 (60.3)
|
72 (52.6)
|
157 (56.47)
|
|
|
Indication for enoxaparin(choose as many as apply) (choice=Deep vein thrombosis): N(%)
|
|
|
|
0.07
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Unchecked
|
71 (50.4)
|
85 (62.0)
|
156 (56.12)
|
|
|
Checked
|
70 (49.6)
|
52 (38.0)
|
122 (43.88)
|
|
|
Indication for enoxaparin(choose as many as apply) (choice=Atrial fibrillation): N(%)
|
|
|
|
0.38
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Unchecked
|
117 (83.0)
|
107 (78.1)
|
224 (80.58)
|
|
|
Checked
|
24 (17.0)
|
30 (21.9)
|
54 (19.42)
|
|
|
Indication for enoxaparin(choose as many as apply) (choice=Myocardial infarction): N(%)
|
|
|
|
0.62
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Unchecked
|
140 (99.3)
|
135 (98.5)
|
275 (98.92)
|
|
|
Checked
|
1 (0.7)
|
2 (1.5)
|
3 (1.08)
|
|
|
Indication for enoxaparin(choose as many as apply) (choice=Metallic heart valve): N(%)
|
|
|
|
0.73
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Unchecked
|
136 (96.5)
|
130 (94.9)
|
266 (95.68)
|
|
|
Checked
|
5 (3.5)
|
7 (5.1)
|
12 (4.32)
|
|
|
Indication for enoxaparin (Other): N(%)
|
|
|
|
1.00
|
|
Missing
|
0 (0.0)
|
0 (0.0)
|
0 (0.00)
|
|
|
Yes
|
140 (99.3)
|
137 (100.0)
|
277 (99.64)
|
|
|
Other/Unknown
|
1 (0.7)
|
0 (0.0)
|
1 (0.36)
|
|
Subgroups
Anti-Xa >1.0 IU/mL
|
Characteristic
|
Conventional (n=45)
|
Non-conventional (n=26)
|
Total (n=71)
|
P-value
|
|
CrCl (mL/min): N(%)
|
|
|
|
0.94
|
|
<50 ml/min
|
19 (42.2)
|
12 (46.2)
|
31 (43.66)
|
|
|
≥50 ml/min
|
26 (57.8)
|
14 (53.8)
|
40 (56.34)
|
|
|
BMI: N(%)
|
|
|
|
0.12
|
|
<30 kg/m2
|
16 (35.6)
|
15 (57.7)
|
31 (43.66)
|
|
|
≥30 kg/m2
|
29 (64.4)
|
11 (42.3)
|
40 (56.34)
|
|
|
Age (y)at the time of result: N(%)
|
|
|
|
0.60
|
|
<65 years
|
18 (40.0)
|
8 (30.8)
|
26 (36.62)
|
|
|
≥65 years
|
27 (60.0)
|
18 (69.2)
|
45 (63.38)
|
|
Anti-Xa <0.5 IU/mL
|
Characteristic
|
Conventional (n=13)
|
Non-conventional (n=23)
|
Total (n=36)
|
P-value
|
|
CrCl (mL/min): N(%)
|
|
|
|
0.14
|
|
<50 ml/min
|
5 (38.5)
|
16 (69.6)
|
21 (58.33)
|
|
|
≥50 ml/min
|
8 (61.5)
|
7 (30.4)
|
15 (41.67)
|
|
|
BMI: N(%)
|
|
|
|
1.00
|
|
<30 kg/m2
|
8 (61.5)
|
15 (65.2)
|
23 (63.89)
|
|
|
≥30 kg/m2
|
5 (38.5)
|
8 (34.8)
|
13 (36.11)
|
|
|
Age (y)at the time of result: N(%)
|
|
|
|
0.69
|
|
<65 years
|
4 (30.8)
|
5 (21.7)
|
9 (25.00)
|
|
|
≥65 years
|
9 (69.2)
|
18 (78.3)
|
27 (75.00)
|
|
Model 1: All patients
Anti-Xa
Model specifications - Outcome: LMWH level - Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency - Model: Multiple linear regression     Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
Global test
|
model term
|
df1
|
df2
|
F.ratio
|
p.value
|
|
individualised_dose_used
|
1
|
272
|
7.887
|
0.005
|
|
age
|
1
|
272
|
0.065
|
0.8
|
|
modified_cg
|
1
|
272
|
0.443
|
0.5
|
|
bmi
|
1
|
272
|
4.353
|
0.04
|
|
enoxaparin_freq
|
1
|
272
|
1.487
|
0.2
|
Model summary
|
Var
|
Coefficients (95% CI)
|
P-value
|
|
(Intercept)
|
-0.392 (-0.793, 0.010)
|
0.06
|
|
individualised_dose_usedNon-conventional
|
-0.136 (-0.231, -0.041)
|
0.005
|
|
age
|
0.001 (-0.004, 0.005)
|
0.8
|
|
modified_cg
|
-0.001 (-0.003, 0.001)
|
0.5
|
|
bmi
|
0.005 (0.000, 0.009)
|
0.04
|
|
enoxaparin_freqTwice daily
|
0.079 (-0.048, 0.207)
|
0.2
|
Model diagnostics
Results
Dosing strategy
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
(Non-conventional) / Conventional
|
0.873 (0.793, 0.960)
|
0.005
|
Adjusted means (95% CI)
|
individualised_dose_used
|
response
|
SE
|
df
|
lower.CL
|
upper.CL
|
|
Conventional
|
0.812
|
0.031
|
272
|
0.753
|
0.876
|
|
Non-conventional
|
0.709
|
0.028
|
272
|
0.656
|
0.766
|
Modified CrCl
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
modified_cg61 / modified_cg60
|
0.999 (0.997, 1.001)
|
0.5
|
BMI
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
bmi30 / bmi29
|
1.005 (1.000, 1.009)
|
0.04
|
Age
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
age67 / age66
|
1.001 (0.996, 1.005)
|
0.8
|
Dose frequency
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
Twice daily / Once daily
|
1.082 (0.952, 1.230)
|
0.2
|
Anti-Xa>1.0
Model specifications - Outcome: LMWH level >1.0 (yes/no) - Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency - Model: Logistic regression     Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
Global test
|
|
LR Chisq
|
Df
|
Pr(>Chisq)
|
|
individualised_dose_used
|
9.484
|
1
|
0.002
|
|
age
|
0.476
|
1
|
0.5
|
|
modified_cg
|
3.641
|
1
|
0.06
|
|
bmi
|
3.815
|
1
|
0.05
|
|
enoxaparin_freq
|
2.739
|
1
|
0.10
|
Model summary
|
Var
|
Coefficients (95% CI)
|
P-value
|
|
(Intercept)
|
-0.754 (-3.104, 1.595)
|
0.5
|
|
individualised_dose_usedNon-conventional
|
-0.918 (-1.517, -0.318)
|
0.003
|
|
age
|
-0.009 (-0.034, 0.016)
|
0.5
|
|
modified_cg
|
-0.011 (-0.023, 0.001)
|
0.06
|
|
bmi
|
0.025 (0.000, 0.050)
|
0.05
|
|
enoxaparin_freqTwice daily
|
0.687 (-0.151, 1.524)
|
0.1
|
Results
Dosing strategy
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
(Non-conventional) / Conventional
|
0.40 (0.22, 0.73)
|
0.003
|
Modified CrCl
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
modified_cg61 / modified_cg60
|
0.99 (0.98, 1.00)
|
0.06
|
BMI
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
bmi30 / bmi29
|
1.03 (1.00, 1.05)
|
0.05
|
Age
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
age67 / age66
|
0.99 (0.97, 1.02)
|
0.5
|
Dose frequency
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
Twice daily / Once daily
|
1.99 (0.86, 4.59)
|
0.1
|
Anti-Xa<0.5
Model specifications - Outcome: LMWH level <0.5 (yes/no) - Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency - Model: Logistic regression     Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
Global test
|
|
LR Chisq
|
Df
|
Pr(>Chisq)
|
|
individualised_dose_used
|
4.859
|
1
|
0.03
|
|
age
|
0.058
|
1
|
0.8
|
|
modified_cg
|
0.006
|
1
|
0.9
|
|
bmi
|
5.938
|
1
|
0.01
|
|
enoxaparin_freq
|
1.512
|
1
|
0.2
|
Model summary
|
Var
|
Coefficients (95% CI)
|
P-value
|
|
(Intercept)
|
-0.226 (-3.435, 2.982)
|
0.9
|
|
individualised_dose_usedNon-conventional
|
0.826 (0.076, 1.576)
|
0.03
|
|
age
|
-0.004 (-0.036, 0.028)
|
0.8
|
|
modified_cg
|
0.001 (-0.014, 0.015)
|
0.9
|
|
bmi
|
-0.049 (-0.093, -0.005)
|
0.03
|
|
enoxaparin_freqTwice daily
|
-0.560 (-1.438, 0.319)
|
0.2
|
Results
Dosing strategy
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
(Non-conventional) / Conventional
|
2.28 (1.08, 4.84)
|
0.03
|
Modified CrCl
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
modified_cg61 / modified_cg60
|
1.00 (0.99, 1.01)
|
0.9
|
BMI
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
bmi30 / bmi29
|
0.95 (0.91, 0.99)
|
0.03
|
Age
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
age67 / age66
|
1.00 (0.96, 1.03)
|
0.8
|
Dose frequency
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
Twice daily / Once daily
|
0.57 (0.24, 1.38)
|
0.2
|
Model 2: Conventionally dosed patients
Anti-Xa
Model specifications - Outcome: LMWH level - Covariates: age, modified CrCl, BMI, dosing frequency - Model: Multiple linear regression     Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
dat_run2 <- dat_run[dat_run$individualised_dose_used%in%"Conventional",]
Global test
|
model term
|
df1
|
df2
|
F.ratio
|
p.value
|
|
age
|
1
|
136
|
0.067
|
0.8
|
|
modified_cg
|
1
|
136
|
4.485
|
0.04
|
|
bmi
|
1
|
136
|
5.469
|
0.02
|
|
enoxaparin_freq
|
1
|
136
|
4.915
|
0.03
|
Model summary
|
Var
|
Coefficients (95% CI)
|
P-value
|
|
(Intercept)
|
-0.405 (-0.939, 0.129)
|
0.1
|
|
age
|
-0.001 (-0.006, 0.005)
|
0.8
|
|
modified_cg
|
-0.003 (-0.006, -0.000)
|
0.04
|
|
bmi
|
0.009 (0.001, 0.017)
|
0.02
|
|
enoxaparin_freqTwice daily
|
0.221 (0.026, 0.416)
|
0.03
|
Model diagnostics
Results
Modified CrCl
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
modified_cg61 / modified_cg60
|
0.997 (0.994, 1.000)
|
0.04
|
BMI
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
bmi30 / bmi29
|
1.009 (1.001, 1.017)
|
0.02
|
Age
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
age67 / age66
|
0.999 (0.994, 1.005)
|
0.8
|
Dose frequency
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
Twice daily / Once daily
|
1.247 (1.024, 1.519)
|
0.03
|
Anti-Xa>1.0
Model specifications - Outcome: LMWH level >1.0 (yes/no) - Covariates: age, modified CrCl, BMI, dosing frequency - Model: Logistic regression     Anti-Xa level ~ age + modified CrCl + BMI + enoxaparin_freq
Global test
|
|
LR Chisq
|
Df
|
Pr(>Chisq)
|
|
age
|
2.981
|
1
|
0.08
|
|
modified_cg
|
9.309
|
1
|
0.002
|
|
bmi
|
5.865
|
1
|
0.02
|
|
enoxaparin_freq
|
4.568
|
1
|
0.03
|
Model summary
|
Var
|
Coefficients (95% CI)
|
P-value
|
|
(Intercept)
|
0.035 (-3.020, 3.091)
|
1.0
|
|
age
|
-0.029 (-0.061, 0.004)
|
0.09
|
|
modified_cg
|
-0.026 (-0.044, -0.008)
|
0.004
|
|
bmi
|
0.054 (0.009, 0.100)
|
0.02
|
|
enoxaparin_freqTwice daily
|
1.312 (0.059, 2.566)
|
0.04
|
Results
Modified CrCl
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
modified_cg61 / modified_cg60
|
0.97 (0.96, 0.99)
|
0.004
|
BMI
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
bmi30 / bmi29
|
1.06 (1.01, 1.10)
|
0.02
|
Age
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
age67 / age66
|
0.97 (0.94, 1.00)
|
0.09
|
Dose frequency
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
Twice daily / Once daily
|
3.72 (1.06, 13.01)
|
0.04
|
Anti-xa<0.5
Model specifications - Outcome: lmwh level <0.5 (yes/no) - Covariates: age, modified crcl, bmi, dosing frequency - Model: Logistic regression     Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq
Global test
|
|
LR Chisq
|
Df
|
Pr(>Chisq)
|
|
age
|
0.176
|
1
|
0.7
|
|
modified_cg
|
1.482
|
1
|
0.2
|
|
bmi
|
1.396
|
1
|
0.2
|
|
enoxaparin_freq
|
3.631
|
1
|
0.06
|
Model summary
|
Var
|
Coefficients (95% CI)
|
P-value
|
|
(Intercept)
|
-1.393 (-6.752, 3.966)
|
0.6
|
|
age
|
0.011 (-0.042, 0.064)
|
0.7
|
|
modified_cg
|
0.015 (-0.010, 0.040)
|
0.2
|
|
bmi
|
-0.052 (-0.146, 0.043)
|
0.3
|
|
enoxaparin_freqTwice daily
|
-1.592 (-3.232, 0.049)
|
0.06
|
Results
Modified CrCl
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
modified_cg61 / modified_cg60
|
1.02 (0.99, 1.04)
|
0.2
|
BMI
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
bmi30 / bmi29
|
0.95 (0.86, 1.04)
|
0.3
|
Age
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
age67 / age66
|
1.01 (0.96, 1.07)
|
0.7
|
Dose frequency
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
Twice daily / Once daily
|
0.20 (0.04, 1.05)
|
0.06
|
Model 3: Individually dosed patients
Anti-Xa
Model specifications - Outcome: LMWH level - Covariates: age, modified CrCl, BMI, dosing frequency - Model: Multiple linear regression     Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
Global test
|
model term
|
df1
|
df2
|
F.ratio
|
p.value
|
|
age
|
1
|
132
|
0.079
|
0.8
|
|
modified_cg
|
1
|
132
|
0.468
|
0.5
|
|
bmi
|
1
|
132
|
0.885
|
0.3
|
|
enoxaparin_freq
|
1
|
132
|
0.003
|
1.0
|
Model summary
|
Var
|
Coefficients (95% CI)
|
P-value
|
|
(Intercept)
|
-0.515 (-1.141, 0.111)
|
0.1
|
|
age
|
0.001 (-0.005, 0.007)
|
0.8
|
|
modified_cg
|
0.001 (-0.002, 0.004)
|
0.5
|
|
bmi
|
0.003 (-0.003, 0.008)
|
0.3
|
|
enoxaparin_freqTwice daily
|
0.005 (-0.166, 0.176)
|
1.0
|
Model diagnostics
Results
Modified CrCl
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
modified_cg61 / modified_cg60
|
1.001 (0.998, 1.004)
|
0.5
|
BMI
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
bmi30 / bmi29
|
1.003 (0.997, 1.008)
|
0.3
|
Age
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
age67 / age66
|
1.001 (0.994, 1.007)
|
0.8
|
Dose frequency
|
Contrast
|
Ratio of Geometric means (95% CI)
|
P-value
|
|
Twice daily / Once daily
|
1.005 (0.846, 1.194)
|
1.0
|
Anti-xa>1.0
Model specifications - Outcome: lmwh level >1.0 (yes/no) - Covariates: age, modified crcl, bmi, dosing frequency - Model: Logistic regression     Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq
Global test
|
|
LR Chisq
|
Df
|
Pr(>Chisq)
|
|
age
|
0.898
|
1
|
0.3
|
|
modified_cg
|
0.279
|
1
|
0.6
|
|
bmi
|
0.974
|
1
|
0.3
|
|
enoxaparin_freq
|
0.407
|
1
|
0.5
|
Model summary
|
Var
|
Coefficients (95% CI)
|
P-value
|
|
(Intercept)
|
-3.990 (-8.124, 0.144)
|
0.06
|
|
age
|
0.020 (-0.022, 0.062)
|
0.3
|
|
modified_cg
|
0.005 (-0.013, 0.022)
|
0.6
|
|
bmi
|
0.017 (-0.016, 0.049)
|
0.3
|
|
enoxaparin_freqTwice daily
|
0.380 (-0.817, 1.578)
|
0.5
|
Results
Modified CrCl
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
modified_cg61 / modified_cg60
|
1.00 (0.99, 1.02)
|
0.6
|
BMI
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
bmi30 / bmi29
|
1.02 (0.98, 1.05)
|
0.3
|
Age
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
age67 / age66
|
1.02 (0.98, 1.06)
|
0.3
|
Dose frequency
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
Twice daily / Once daily
|
1.46 (0.44, 4.84)
|
0.5
|
Anti-xa<0.5
Model specifications - Outcome: lmwh level <0.5 (yes/no) - Covariates: age, modified crcl, bmi, dosing frequency - Model: Logistic regression     Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq
Global test
|
|
LR Chisq
|
Df
|
Pr(>Chisq)
|
|
age
|
0.149
|
1
|
0.7
|
|
modified_cg
|
0.339
|
1
|
0.6
|
|
bmi
|
4.174
|
1
|
0.04
|
|
enoxaparin_freq
|
0.098
|
1
|
0.8
|
Model summary
|
Var
|
Coefficients (95% CI)
|
P-value
|
|
(Intercept)
|
0.900 (-3.482, 5.282)
|
0.7
|
|
age
|
-0.009 (-0.052, 0.035)
|
0.7
|
|
modified_cg
|
-0.006 (-0.025, 0.014)
|
0.6
|
|
bmi
|
-0.047 (-0.097, 0.003)
|
0.07
|
|
enoxaparin_freqTwice daily
|
-0.177 (-1.271, 0.918)
|
0.8
|
Results
Modified CrCl
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
modified_cg61 / modified_cg60
|
0.99 (0.98, 1.01)
|
0.6
|
BMI
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
bmi30 / bmi29
|
0.95 (0.91, 1.00)
|
0.06
|
Age
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
age67 / age66
|
0.99 (0.95, 1.04)
|
0.7
|
Dose frequency
|
Contrast
|
Odds ratios (95% CI)
|
P-value
|
|
Twice daily / Once daily
|
0.84 (0.28, 2.50)
|
0.8
|
Session info
Results generated on: 2023-11-03 21:18:56.546987
Click for more details
## R version 4.3.1 (2023-06-16)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.3 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
##
## locale:
## [1] LC_CTYPE=en_AU.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_AU.UTF-8 LC_COLLATE=en_AU.UTF-8
## [5] LC_MONETARY=en_AU.UTF-8 LC_MESSAGES=en_AU.UTF-8
## [7] LC_PAPER=en_AU.UTF-8 LC_NAME=en_AU.UTF-8
## [9] LC_ADDRESS=en_AU.UTF-8 LC_TELEPHONE=en_AU.UTF-8
## [11] LC_MEASUREMENT=en_AU.UTF-8 LC_IDENTIFICATION=en_AU.UTF-8
##
## time zone: Australia/Adelaide
## tzcode source: system (glibc)
##
## attached base packages:
## [1] splines grid stats graphics grDevices utils datasets methods
## [9] base
##
## other attached packages:
## [1] progress_1.2.2 Hmisc_5.1-0 REDCapR_1.1.0 xlsx_0.6.5
## [5] ggpubr_0.6.0 DiagrammeR_1.0.10 car_3.1-2 carData_3.0-5
## [9] fontawesome_0.5.2 MASS_7.3-60 emmeans_1.8.8 plotly_4.10.2
## [13] readxl_1.4.3 htmlwidgets_1.6.2 kableExtra_1.3.4 knitr_1.43
## [17] ggplot2_3.4.3 devtools_2.4.3 usethis_2.2.2 pander_0.6.5
## [21] magrittr_2.0.3 gridExtra_2.3 rmarkdown_2.24 nvimcom_0.9-145
##
## loaded via a namespace (and not attached):
## [1] remotes_2.4.2.1 sandwich_3.0-2 rlang_1.1.1 multcomp_1.4-25
## [5] compiler_4.3.1 systemfonts_1.0.4 callr_3.7.3 vctrs_0.6.3
## [9] rvest_1.0.3 stringr_1.5.0 pkgconfig_2.0.3 crayon_1.5.2
## [13] fastmap_1.1.1 backports_1.4.1 ellipsis_0.3.2 labeling_0.4.3
## [17] utf8_1.2.3 sessioninfo_1.2.2 ps_1.7.5 purrr_1.0.2
## [21] xfun_0.40 cachem_1.0.8 jsonlite_1.8.7 highr_0.10
## [25] xlsxjars_0.6.1 broom_1.0.5 prettyunits_1.1.1 cluster_2.1.4
## [29] R6_2.5.1 bslib_0.5.1 stringi_1.7.12 RColorBrewer_1.1-3
## [33] rpart_4.1.21 pkgload_1.3.2.1 jquerylib_0.1.4 cellranger_1.1.0
## [37] estimability_1.4.1 Rcpp_1.0.11 zoo_1.8-12 base64enc_0.1-3
## [41] nnet_7.3-19 Matrix_1.6-1.1 tidyselect_1.2.0 rstudioapi_0.15.0
## [45] abind_1.4-5 yaml_2.3.7 codetools_0.2-19 processx_3.8.2
## [49] pkgbuild_1.4.2 lattice_0.22-5 tibble_3.2.1 withr_2.5.0
## [53] coda_0.19-4 evaluate_0.21 foreign_0.8-85 survival_3.5-7
## [57] rJava_1.0-6 xml2_1.3.5 pillar_1.9.0 checkmate_2.2.0
## [61] generics_0.1.3 hms_1.1.3 munsell_0.5.0 scales_1.2.1
## [65] xtable_1.8-4 glue_1.6.2 lazyeval_0.2.2 tools_4.3.1
## [69] data.table_1.14.8 webshot_0.5.5 ggsignif_0.6.4 fs_1.6.3
## [73] visNetwork_2.1.2 mvtnorm_1.2-3 tidyr_1.3.0 colorspace_2.1-0
## [77] htmlTable_2.4.1 Formula_1.2-5 cli_3.6.1 fansi_1.0.4
## [81] viridisLite_0.4.2 svglite_2.1.1 dplyr_1.1.3 gtable_0.3.4
## [85] rstatix_0.7.2 sass_0.4.7 digest_0.6.33 TH.data_1.1-2
## [89] farver_2.1.1 memoise_2.0.1 htmltools_0.5.6 lifecycle_1.0.3
## [93] httr_1.4.7